Conference Coverage
Latest News
Jun 10, 2026 | News
FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer
Kevin Zorn, MD, on selecting among different MIST options for BPH
Jun 10, 2026
Pearls & Perspectives: The Evolving Landscape of Female Pelvic Health, With Annah J. Vollstedt, MD
Jun 09, 2026
Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure
Jun 09, 2026
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
Jun 08, 2026
Advertisement
Shorts
1:02
The UroOnc Minute: Patient selection for MDT in the PSMA-PET era
a day ago
by
Adam B. Weiner, MD(+1 more)
0:55
Archan Khandekar, MD, on the future for AI in urology
2 days ago
by
Archan Khandekar, MD
0:45
Praful Ravi, MB, BChir, MRCP, on residual disease detection using PSMA-PET
5 days ago
by
Praful Ravi, MB, BChir, MRCP
0:28
What BULLSEYE's PFS data should—and shouldn't—mean
6 days ago
by
James Nagarajah, MD
0:28
Why Break Wave Lithotripsy is a game changer for stone care
7 days ago
by
Ben H. Chew, MD, MSc
0:40
Aleece Fosnight, MSPAS, PA-C, on what to tell patients about microplastics and bladder health
8 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:47
Louise Emmett, MD, PhD, MBChB, FRACP, on the potential role of 225Ac-PSMA-617 earlier in mCRPC
9 days ago
0:35
Lucia Nappi, MD, on the future for miR371 in testicular cancer
10 days ago
by
Lucia Nappi, MD, PhD, FRCPC
0:42
Joshua Lang, MD, MS, highlights emerging biomarker strategies in GU oncology
11 days ago
by
Joshua Lang, MD, MS
1:24
Integrating immunotherapy into newly diagnosed MIBC
12 days ago
by
María Natalia Gandur Quiroga, MD, MSc
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Abigail Keller, MD, shares findings showing that nadofaragene firadenovec is associated with increased urine production during instillation compared with gemcitabine/docetaxel.
Clint D. Bahler, MD, reflects on key prostate cancer themes from AUA 2026, including the shift toward more personalized care.
In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Chad Tang, MD, to discuss findings from the WOLVERINE meta-analysis, evaluating the effectiveness of metastasis-directed therapy for oligometastatic prostate cancer.
The primary end point—12-month DFS rate—was 80% (40/50 evaluable patients; 95% CI, 0.67-0.89), with 2 patients pending assessment and 3 not evaluable.
The pivotal trial is assessing the non-inferiority of the Separo Vessel Sealing System vs conventional mucosal cautery vasectomy.
Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer.
A recap of the FDA submissions and regulatory decisions in urology from May 2026.
Titan Prime will be available in the US via a phased launch beginning in late 2026.
In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Tom Riester of LTR Pharma about the development of a novel intranasal therapy for erectile dysfunction, exploring its potential implications for sexual health, prostate cancer survivorship, and broader engagement in men's health care.
Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC.
Advertisement
PSA50 response rates were 58.8% overall in Group A (72.7% at 10 MBq), 85.2% overall in Group B (100% at 10 MBq), and 52.5% overall in Group C (56.3% at 10 MBq).
Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.
"Together with the efficacy and safety results, these PRO findings support the overall benefit-risk profile of perioperative EV plus [pembrolizumab] as the new standard of care in this patient population," said Peter H. O'Donnell, MD.
Kim Chi, MD, highlights findings from a pre-planned analysis of the PLUDO trial examining the impact of crossover on survival outcomes between 177Lu-PSMA-617 vs docetaxel in mCRPC.
The FDA approved cefepime and zidebactam for adult complicated UTI after ENHANCE-1 showed an 89.0% response rate at test of cure.
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
3
Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure
4
FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer
5